Our treatment is a once-weekly injection, and a synthetic GLP-1 RA (receptor agonist)
Integrative proteomics, genomics, and translational immunology approaches reveal mutated forms of Proteolipid Protein 1 (PLP1) and mutant-specific immune response in multiple sclerosis
[DOI] [PubMed] [Google Scholar] [93].VanPatten S, Sun S, He M
Discuss both options with your Maximus physician during the consultation process
While conclusive evidence is pending, the convergence of mechanistic, preclinical, and clinical data makes GLP-1 inhibitors one of the most promising emerging approaches to substance use disorders
Now the challenge was to find a small molecule that also fits that pocket